Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia

Amy Crowe, Nicole McMahon, Bart Currie, Robert Baird

Research output: Contribution to journalArticleResearchpeer-review

2 Downloads (Pure)

Abstract

Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.
Original languageEnglish
Pages (from-to)160-162
Number of pages3
JournalInternational Journal of Antimicrobial Agents
Volume44
Issue number2
DOIs
Publication statusPublished - Aug 2014

Fingerprint

Northern Territory
Melioidosis
Burkholderia pseudomallei
meropenem
Sulfamethoxazole Drug Combination Trimethoprim
Ceftazidime
Disk Diffusion Antimicrobial Tests
Northern Asia
Southeastern Asia
Doxycycline
Thailand
Gram-Negative Bacteria
Communicable Diseases
Guidelines

Cite this

@article{2ca6a63123e24b109d08e8c8a0153852,
title = "Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia",
abstract = "Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6{\%}) were susceptible to doxycycline and 232 (99.1{\%}) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.",
keywords = "ceftazidime, cotrimoxazole, doxycycline, meropenem, antiinfective agent, thienamycin derivative, antibiotic resistance, antibiotic sensitivity, article, Australia, bacterium isolate, Burkholderia pseudomallei, controlled study, disease duration, geographic origin, melioidosis, minimum inhibitory concentration, nonhuman, onset age, priority journal, drug effects, human, isolation and purification, microbial sensitivity test, microbiology, root cause analysis, Anti-Bacterial Agents, Ceftazidime, Drug Resistance, Bacterial, Humans, Melioidosis, Microbial Sensitivity Tests, Northern Territory, Root Cause Analysis, Thienamycins, Trimethoprim-Sulfamethoxazole Combination",
author = "Amy Crowe and Nicole McMahon and Bart Currie and Robert Baird",
year = "2014",
month = "8",
doi = "10.1016/j.ijantimicag.2014.04.012",
language = "English",
volume = "44",
pages = "160--162",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. / Crowe, Amy; McMahon, Nicole; Currie, Bart; Baird, Robert.

In: International Journal of Antimicrobial Agents, Vol. 44, No. 2, 08.2014, p. 160-162.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia

AU - Crowe, Amy

AU - McMahon, Nicole

AU - Currie, Bart

AU - Baird, Robert

PY - 2014/8

Y1 - 2014/8

N2 - Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.

AB - Burkholderia pseudomallei is a saprophytic Gram-negative bacterium responsible for the tropical infectious disease melioidosis. Melioidosis is endemic to northern Australia and Southeast Asia. In this study, 234 isolates of B. pseudomallei obtained from the first positive clinical specimen from 234 consecutive patients diagnosed with melioidosis between October 2009 and September 2012 were reviewed. All isolates were susceptible to meropenem and ceftazidime. In total, 226 isolates (96.6%) were susceptible to doxycycline and 232 (99.1%) were susceptible to trimethoprim/sulfamethoxazole (TMP/SMX; co-trimoxazole). Primary resistance of B. pseudomallei to ceftazidime and/or meropenem is exceedingly rare and clinicians can be confident in the current treatment guidelines for melioidosis. Whether the very low rates of TMP/SMX resistance seen in Australia reflect the global situation requires further studies using Etest, especially to clarify the rate of resistance in Thailand.

KW - ceftazidime

KW - cotrimoxazole

KW - doxycycline

KW - meropenem

KW - antiinfective agent

KW - thienamycin derivative

KW - antibiotic resistance

KW - antibiotic sensitivity

KW - article

KW - Australia

KW - bacterium isolate

KW - Burkholderia pseudomallei

KW - controlled study

KW - disease duration

KW - geographic origin

KW - melioidosis

KW - minimum inhibitory concentration

KW - nonhuman

KW - onset age

KW - priority journal

KW - drug effects

KW - human

KW - isolation and purification

KW - microbial sensitivity test

KW - microbiology

KW - root cause analysis

KW - Anti-Bacterial Agents

KW - Ceftazidime

KW - Drug Resistance, Bacterial

KW - Humans

KW - Melioidosis

KW - Microbial Sensitivity Tests

KW - Northern Territory

KW - Root Cause Analysis

KW - Thienamycins

KW - Trimethoprim-Sulfamethoxazole Combination

U2 - 10.1016/j.ijantimicag.2014.04.012

DO - 10.1016/j.ijantimicag.2014.04.012

M3 - Article

VL - 44

SP - 160

EP - 162

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -